PARa-aOrtic LymphAdenectomy in Locally Advanced Cervical Cancer

This is an international, multicenter and randomized open-label phase III study designed to demonstrate, in patients with stage IIIC1 cervical cancer, whether para-aortic lymphadenectomy followed by tailored chemoradiation is associated with increased disease-free survival compared to patients staged with FDG-PET/CT only followed by chemoradiation. The planned sample size is 510; including 200 patients in France. In this trial, patients will be assigned in one of the two following treatments arms: * Arm A (control arm): Standard chemo-radiotherapy and brachytherapy according to EMBRACE II a

Trial Details

NCT ID
NCT05581121
Phase
PHASE3
Sponsor
Institut Claudius Regaud
Status
RECRUITING
Cancer Type
Adenocarcinoma Cervical Cancer
Interventions
  • Standard treatment: Control arm
  • Experimental arm
Locations (sample)
  • Ostrava, Czechia|49.83465,18.28204
  • Pilsen, Czechia|49.74747,13.37759
  • Prague, Czechia|50.08804,14.42076
  • Angers, France|47.47156,-0.55202
  • Bordeaux, France|44.84124,-0.58046

Key Eligibility Criteria

  • Age ≥ 18 years at time of study entry
  • Newly diagnosed histologically proven cervical squamous carcinoma, adenocarcinoma, or adenosquamous tumor
  • FIGO stage IIIC1 (FIGO 2018) cervical cancer with FDG-PET/CT showing FDG-positive pelvic nodes and FDG-negative PALN including equivocal lymph node…
  • Patients with TNM T stage I-IIIB.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Adenocarcinoma Cervical Cancer Trials on Trialify →